BRCA1 underexpression
|
Bladder Cancer
|
BRCA1 underexpression
|
Bladder Cancer
|
cisplatin + gemcitabine Sensitive: C3 – Early Trials
|
cisplatin + gemcitabine Sensitive: C3 – Early Trials
|
BRCA1 underexpression
|
Prostate Cancer
|
BRCA1 underexpression
|
Prostate Cancer
|
PARP inhibitor Sensitive: D – Preclinical
|
PARP inhibitor Sensitive: D – Preclinical
|